Skip to main content

Table 2 Correlation of MDM2 immunostaining with tumor site, size, mitotic count, necrosis, tumor risk, and metastastatic status

From: The expression of MDM2 in gastrointestinal stromal tumors: immunohistochemical analysis of 35 cases

Variables MDM2 negative (%) MDM2 positive (%) P value
Tumor site:
 Stomach 11/17 (64.70%) 6/17 (35.29%) 0.87
 S. bowel 5/9 (55.55%) 4/9 (44.44%)
 Peritoneum 3/5 (60%) 2/5 (40%)
 Duodenum 1/3 (33.33%) 2/3 (66.66%)
 Colon 1/1 (100%) 0/1 (0%)
Size (cm):
  ≤ 5 7/8 (87.5%) 1/8 (12.5%) 0.08
 5˂ S ≤ 10 7/17 (41.17%) 10/17 (58.82%)
  > 10 7/10 (70%) 3/10 (30%)
Mitotic count/50 HPF:
  ≤ 5 11/14 (78.57%) 3/14 (21.42%) 0.06
  > 5 10/21 (47.61%) 11/21 (52.38%)
Necrosis:
 Absent 18/27 (66.66%) 9/27 (33.33%) 0.14
 Present 3/8 (37.5%) 5/8 (62.5%)
Risk:
 Very low 2/2 (100%) 0/2 (0%) 0.34
 Low 4/5 (80%) 1/5 (20%)
 Intermediate 5/7 (71.42%) 2/7 (28.57%)
 High 10/21 (47.61%) 11/21 (52.38%)
Metastasis:
 Absent 20/26 (76.92%) 6/26 (23.07%) 0.001
 Present 1/9 (11.11%) 8/9 (88.88%)
\